Evidence map›Paper›PMID 29731882›Full record

ArticleOncology letters2018

Autologous stem cell transplantation in EBV-positive post-renal transplant refractory multiple myeloma: A case report and literature review.

Xiaobao Xie, Yan Lin, Yang Cao, Weimin Dong, Wei Wu, Yuandong Zhu, Deliang Liu, Haiqian Li, Qing Li, Weiying Gu

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Xiaobao XieDepartment of Hematology, The First People's Hospital of Changzhou, The Third Affiliated Hospital of Suzhou University, Changzhou, Jiangsu 213003, P.R. China.
Yan LinDepartment of Hematology, The First People's Hospital of Changzhou, The Third Affiliated Hospital of Suzhou University, Changzhou, Jiangsu 213003, P.R. China.
Yang CaoDepartment of Hematology, The First People's Hospital of Changzhou, The Third Affiliated Hospital of Suzhou University, Changzhou, Jiangsu 213003, P.R. China.
Weimin DongDepartment of Hematology, The First People's Hospital of Changzhou, The Third Affiliated Hospital of Suzhou University, Changzhou, Jiangsu 213003, P.R. China.
Wei WuDepartment of Hematology, The First People's Hospital of Changzhou, The Third Affiliated Hospital of Suzhou University, Changzhou, Jiangsu 213003, P.R. China.
Yuandong ZhuDepartment of Hematology, The First People's Hospital of Changzhou, The Third Affiliated Hospital of Suzhou University, Changzhou, Jiangsu 213003, P.R. China.
Deliang LiuDepartment of Hematology, The First People's Hospital of Changzhou, The Third Affiliated Hospital of Suzhou University, Changzhou, Jiangsu 213003, P.R. China.
Haiqian LiDepartment of Hematology, The First People's Hospital of Changzhou, The Third Affiliated Hospital of Suzhou University, Changzhou, Jiangsu 213003, P.R. China.
Qing LiDepartment of Pathology, The First People's Hospital of Changzhou, The Third Affiliated Hospital of Suzhou University, Changzhou, Jiangsu 213003, P.R. China.
Weiying GuDepartment of Hematology, The First People's Hospital of Changzhou, The Third Affiliated Hospital of Suzhou University, Changzhou, Jiangsu 213003, P.R. China.
The First People's Hospital of Changzhou · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal transplant recipients exhibit an increased risk of developing plasma cell neoplasms (PCNs; comprising multiple myeloma and plasmacytoma); however, multiple myeloma manifesting with refractory extramedullary plasmacytomas associated with Epstein-Barr virus are markedly rare in these patients. In the present case report, an unusual case of refractory multiple myeloma with multiple extramedullary plasmacytoma (including liver, vertebrae, breast, muscle, skin and soft tissues) was presented. The patient exhibited mild bone marrow infiltration which was successfully treated with novel agents, including bortezomib and lenalidomide, followed by autologous stem cell transplantation (ASCT). In addition, the patient was a renal transplant recipient who achieved a partial clinical remission with controllable therapy-related toxicity effects. Therefore, the present case indicated that ASCT is an effective and safe salvage therapy for renal transplant recipients with secondary extramedullary plasmacytomas and who are resistant to traditional chemotherapy (bortezomib and lenalidomide). ASCT was well-tolerated in the renal transplant recipient.

Indexed as

autologous stem cell transplantationlenalidomidemultiple myelomarefractoryrenal transplant

Identifiers

PMID29731882
PMCPMC5921225
OpenAlexW2790717876

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.